Less than a week after Jeremy Levin resigned as CEO of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA), another reason for the move has emerged - and it may be the main reason: an investigation of leaks from the board of directors that he instituted. Six months ago, Levin demanded an investigation, which was carried out by Wizman Yaar Investigations. As part of the investigation, Israeli directors at Teva underwent polygraph tests and were questioned about telephone conversations, which were shown to them.
Help employers find you! Check out all the jobs and post your resume.
